Paxmedica, INC 8-K filings

PaxMedica announces the resignation of its Chairman and two directors in connection with its transition to becoming a wholly-owned subsidiary of PRV, LLC.

PaxMedica has successfully induced the immediate exercise of existing warrants at a reduced price, generating $884,616 in gross proceeds and issuing new warrants for future share purchases.

PaxMedica's Chief Medical Officer, Dr. David Hough, has resigned from his position effective July 16, 2024, due to his retirement.

PaxMedica has received notification from Nasdaq that it no longer meets the minimum stockholders' equity requirement for continued listing, following a previous delisting decision.

PaxMedica's annual meeting saw shareholders approve the election of a director and a reverse stock split, but reject a proposal for officer exculpation.

PaxMedica has filed an appeal against its delisting from Nasdaq and is preparing for a key FDA meeting regarding its drug candidate, PAX-101.

PaxMedica, Inc. has been notified by Nasdaq that its common stock will be delisted due to non-compliance with the minimum bid price rule, and the company expects its shares to trade on the OTC Pink Market.

PaxMedica will provide immediate access to its PAX-101 medication in response to an emergency request from the Ministry of Health of Malawi for the treatment of sleeping sickness.

PaxMedica has received an urgent request from the Ministry of Health of Malawi for emergency access to IV suramin to treat a fatal sleeping sickness due to dwindling supplies.

PaxMedica has completed three pivotal registration/validation batches of PAX-101, a crucial step towards a planned New Drug Application (NDA) submission to the FDA in Q4 2024.

PaxMedica, Inc. has amended its bylaws to reduce the quorum requirement for stockholder meetings to 33.4% of voting power.

PaxMedica is progressing towards FDA approval for its HAT treatment, while also advancing clinical trials for its ASD treatment, PAX-101.

PaxMedica's Board of Directors approved the acceleration of vesting for certain restricted stock units (RSUs) held by key executives to streamline administrative processes and reduce costs.

PaxMedica received a delisting notice from Nasdaq after its share price remained below $1.00 for 31 consecutive trading days, and the company plans to request a hearing to present a plan for regaining compliance.